DAVID DONAHUE: Open Payments
NPI 1871589028 · VENICE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,290 in 106 payments from 19 companies in 2025. Trend: 2023 $1,102 · 2024 $1,845 · 2025 $2,290
Food & beverage: $2,290
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $400 |
| Alkermes, Inc. | 10 | $225 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $208 |
| ABBVIE INC. | 11 | $203 |
| Otsuka America Pharmaceutical, Inc. | 11 | $175 |
| Lundbeck LLC | 7 | $162 |
| Noven Therapeutics, LLC | 8 | $137 |
| Axsome Therapeutics, Inc. | 5 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $116 |
Products named: INGREZZA, REXULTI, CAPLYTA, VRAYLAR, ARISTADA, Xelstrym, Auvelity, TRINTELLIX.
Industry payments across FL — which companies pay providers there.
